CSIMarket Company Name, Ticker, Competitors, else..
 
Elutia Inc   (NASDAQ: ELUT)
 
Price: $0.8641 $-0.02 -1.807%
Day's High: $0.8999999761581421 Week Perf: -14.45 %
Day's Low: $ 0.84 30 Day Perf: 0.83 %
Volume (M): 54,184 52 Wk High: $ 2.38
Volume (M$): $ 0 52 Wk Avg: $0.97
Open: $0.89 52 Wk Low: $0.50



 Market Capitalization (Millions $) 38
 Shares Outstanding (Millions) 44
 Employees 26
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) 52
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 2

Business Description


Elutia Inc is a technology company that specializes in developing innovative solutions for the commercial and industrial sectors. The company focuses on creating high-performance computing systems, embedded computing solutions, and advanced data analytics software. Elutia Inc's products and services are designed to improve operational efficiency, enhance productivity, and optimize decision-making processes for its clients. With a strong emphasis on research and development, the company strives to stay at the forefront of technological advancements and provide cutting-edge solutions to its customers.


   Company Address: 20 Firstfield Road Gaithersburg 20878 MD
   Company Phone Number: 247-1170   Stock Exchange / Ticker: NASDAQ ELUT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IART        1.38% 
• View Complete Report
   



Clinical Study

Elutia Inc. Reports Revenue Growth and Positive Clinical Outcomes for Biologic Envelopes Amid Industry Contraction,

Published Tue, Sep 16 2025 12:42 PM UTC

Elutia Inc. Sees Revenue Growth Amidst Industry Challenges, Highlighted by Positive Clinical Data for Biologic Envelopes In recent announcements, Elutia Inc. has showcased promising developments in both clinical data and financial performance, positioning the company favorably within a competitive landscape. The publication of new clinical data underscores the effectiveness ...
Management Announcement

Elutia Inc. Underscores Resilience Amid Global Tariff Challenges and Highlights Efficacy of EluPro BioEnvelope in Preventing Cardiac Device Infections

Published Mon, Apr 14 2025 12:01 PM UTC

In a significant update from Silver Spring, Maryland, Elutia Inc. (Nasdaq: ELUT), a prominent innovator in the realm of drug-eluting biomatrix products, has confirmed that the ongoing global tariff environment has not materially impacted its commercial or operational performance. This announcement comes at a critical juncture for the company, particularly as it faces market ...
Product Service News

Elutia Inc. a leader in the development of advanced medical devices, has recently unveiled a crucial publi...

Published Wed, Sep 18 2024 12:00 PM UTC

Groundbreaking Study Confirms the Efficacy of Elutia s Antibiotic-Eluting BioEnvelope, EluPro, in Preventing Cardiac Device Infections Elutia Inc. a leader in the development of advanced medical devices, has recently unveiled a crucial publication that underscores the formidable effectiveness of its flagship product, the EluPro Antibiotic-Eluting BioEnvelope. This peer-revie...
Product Service News

Elutia Inc. Breaks New Ground with First Implant of FDA-Cleared EluPro BioEnvelope,

Published Thu, Sep 5 2024 8:05 PM UTC

Elutia Inc. Begins a New Era in Cardiac and Neurostimulation Treatment with EluPro BioEnvelope By Elutia Inc. (Nasdaq: ELUT) has announced a significant milestone in the field of cardiac and neurostimulation therapy with the first successful patient implant of EluPro, the world’s first antibiotic-eluting biologic envelope, sanctioned by the U.S. Food and Drug Administrat...
Stocks on the Move

The Journey of Elutia Inc Struggles, Successes, and FDA Clearance

Published Fri, Jun 28 2024 10:30 AM UTC

Elutia Inc: Struggles and Successes in the Drug Discovery IndustryThe drug discovery industry is a complex field that requires extensive research, testing, and regulatory approval before a new medication can reach the market. Elutia Inc, a pharmaceutical company specializing in drug-eluting biomatrix products, has recently been in the spotlight due to its various development...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 0.68
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.37
Price to Sales (Expected) -
Price to Book 2.43
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.95
Working Capital Ratio 1.77
Leverage Ratio (MRQ) 1.77
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 1.28 $
Revenues (TTM) 0.26 $
Cash Flow (TTM) 0.45 $
Cash 0.45 $
Book Value 0.36 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 436,654
Net Income per Employee (TTM) 1,992,615
Receivable Turnover Ratio (TTM) 5.16
Inventory Turnover Ratio (TTM) 1.75
Asset Turnover Ratio (TTM) 0.24

Profitability Ratios Current
Gross Margin (MRQ) 59.62 %
Operating Margin (MRQ) -327.85 %
Net Margin (MRQ) -315.04 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 108.72 %
Return On Investment (TTM) 218.66 %
Return On Equity (TTM) 940.81 %
Dividend Yield -
Pay out Ratio (TTM) -



Elutia Inc's Segments
Women s Health    89.37 % of total Revenue
Member    228.31 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.